Clinical assessments
The differences between treatment groups and placebo in the median change from baseline at 48 weeks were 3.0 (95%CI, 2.2 to 3.7) in neuroEPO plus 0.5 mg, With respect to ADL, there was not an important variation at week 48. Most patients did not change their initial functional status. However, in the Lawton scale, neuroEPO plus-treated patients maintained the same median value (6.0 ± 4.0), whereas patients in the placebo group decreased the median value by 1 point (5.0 ± 3.0), Table S1, 